High-thermal-stability terminal deoxynucleotidyl transferase mutant and application thereof

By truncating the structure of Zonotrichia albicollis TdT and performing multiple mutations, a heat-resistant terminal deoxynucleotidyl transferase mutant was formed, which solved the problem of poor thermal stability of TdT and improved the efficiency and length of DNA enzymatic synthesis.

CN118995661AActive Publication Date: 2024-11-22ZHEJIANG UNIV

Patent Information

Application Number
CN202411359603.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-27
Publication Date
2024-11-22
Estimated Expiration
2044-09-27

AI Technical Summary

Technical Problem

The existing terminal deoxynucleotidyl transferase (TdT) has poor thermostability, which leads to loss of enzyme activity at high temperatures, affecting the efficiency and effectiveness of DNA enzymatic synthesis.

Method used

By truncating the structure of TdT derived from Zonotrichia albicollis and performing multi-point mutations, a heat-resistant terminal deoxynucleotidyl transferase mutant was formed, thereby improving its thermal stability and unfolding temperature.

Benefits of technology

It improves the thermostability of terminal deoxynucleotidyl transferase, enhances the efficiency and length of DNA enzymatic synthesis, and overcomes the limitations of chemical synthesis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995661A_ABST
    Figure CN118995661A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of enzyme engineering, and particularly relates to a terminal deoxynucleotidyl transferase mutant with high thermal stability and application thereof, and the terminal deoxynucleotidyl transferase mutant is obtained by performing multipoint mutation on an amino acid sequence as shown in SEQ ID NO.1. According to the invention, a series of mutants with improved heat resistance are obtained by carrying out structural truncation on a terminal deoxynucleotidyl transferase TdT wild type derived from Zonotrichia albicola and then carrying out multipoint mutation, and the mutants have better thermal stability and higher unfolding temperature and can play an important role in DNA (deoxyribonucleic acid) enzymatic synthesis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of enzyme engineering, and in particular relates to a terminal deoxynucleotidyl transferase mutant with high thermal stability and application thereof. Background Art

[0002] DNA synthesis is a key technology in the fields of life science, biomedicine, materials science and information storage. Currently, DNA synthesis mainly relies on chemical synthesis, which has insurmountable limits in synthesis length and cost, and cannot meet the growing needs of the biomanufacturing field. Enzymatic DNA synthesis has unparalleled potential in terms of synthesis speed, length, efficiency and cost, and has become the forefront of the development of DNA synthesis technology.

[0003] Terminal deoxynucleotidyl transferase (TdT) is a unique DNA polymerase that can randomly add deoxynucleotides to the initiator under template-independent conditions. Based on the template-independent characteristics of terminal deoxynucleotidyl transferase, it can be used for DNA synthesis. When the growing single-stranded DNA molecule reaches a certain length, a secondary structure will be formed. However, TdT has poor substrate activity for the formation of secondary structure at the 3′-OH end, resulting in reduced extension efficiency. High temperature can destroy the hairpin structure of the primer chain and restore it to a single strand that is easy to extend, but TdT has poor stability. High temperature will cause the enzyme activity to be lost and the catalytic reaction function to be lost. Therefore, improving the thermal stability of TdT is of great significance in DNA enzymatic synthesis. Summary of the invention

[0004] In view of the defect of poor heat resistance of terminal deoxynucleotidyl transferase in the prior art, the present invention provides a terminal deoxynucleotidyl transferase mutant with high thermal stability and its application, and the specific technical scheme is as follows:

[0005] In the first aspect, the present invention provides a terminal deoxynucleotidyl transferase mutant with high thermal stability, wherein the mutant form is one of the following forms:

[0006] (1) The amino acid sequence of SEQ ID NO.2 was mutated to S116A / P301A / L50V / F40R / C173W / A257C / V70F / N192E / L166Q / A322R / Q104L / Y17H / S57T / N91K / I39G / E84H / R89E / K35N / K11R / I82L / G346T / E43A / Y302F / V27I / V164I / S7A / R338T / I232Q / V360I / R340K / N170E / L45R / K339Q / K100Q / I197V / E79Q, and the amino acid sequence is shown in SEQ ID NO.3;

[0007] (2) The amino acid sequence of SEQ ID NO. 2 was modified into S116A / P301A / L50V / F40R / C173W / A257C / V70F / N192E / L166Q / A322R / Q104L / Y17H / S57T / N91K / I39G / E84H / R89E / K35N / K11R / I82L / G346T / E43A / Y3 02F / V27I / V164I / S7A / R338T / I232Q / V360I / R340K / N170E / L45R / K339Q / K100Q / I197V / E79Q / V237D / S139T / Q73H / Q240K / L147Q / K20R / E239S / D358E mutation was obtained, and the amino acid sequence is shown in SEQ ID NO.4;

[0008] (3) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 3 to G314N / Q232I / I328L / E275K / I183M / D76R mutations;

[0009] (4) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 3 to G314N / Q232I / I328L / E275K / I183M / D76R / T270N / R311K / M28L / E92R / A101T mutations;

[0010] (5) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 3 to G314N / Q232I / I328L / E275K / I183M / D76R / T270N / R311K / M28L / E92R / A101T / V237E / T174A / Q240K / K20R / F297W / D358E / C271Y mutations;

[0011] (6) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 4 to G314N / E361P / Q232I mutations;

[0012] (7) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 4 to G314N / E361P / Q232I / I183M mutations;

[0013] (8) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 4 to G314N / E361P / Q232I / I183M / I328L mutations;

[0014] (9) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 4 to G314N / E361P / Q232I / I183M / I328L / N31Y mutations;

[0015] (10) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 4 to G314N / E361P / Q232I / I183M / I328L / N31Y / E275K / D76R mutations;

[0016] (11) The amino acid sequence shown in SEQ ID NO.4 was mutated to G314N / E361P / Q232I / I183M / I328L / N31Y / E275K / D76R / R311K / I288V / C271Y / T174A / K91E / F297Y / E92R / E278D / I294V, and the amino acid sequence is shown in SEQ ID NO.5.

[0017] In the present invention, the terminal deoxynucleotidyl transferase TdT derived from Zonotrichia albicollis is used, and Alphafold 2 is used to construct the three-dimensional structure of TdT. Based on the model scoring, a suitable structure is selected, and the Loop part in its protein structure is truncated to obtain a truncated terminal deoxynucleotidyl transferase. On the basis of the truncated terminal deoxynucleotidyl transferase, the pross online tool based on the energy function is used to predict the mutation site, and multiple point mutations are performed to obtain a terminal deoxynucleotidyl transferase mutant that is more resistant to high temperatures, and its unfolding temperature is increased by up to 9.1°C.

[0018] In a second aspect, the present invention also provides a terminal deoxynucleotidyl transferase mutant obtained by subjecting the above mutant to R189L / K191G mutation.

[0019] Furthermore, the mutant with the amino acid sequence as shown in SEQ ID NO.5 is subjected to R189L / K191G mutation to obtain the mutant.

[0020] Studies have shown (Enzymatic DNA Synthesis by Engineering Terminal Deoxynucleotidyl Transferase|ACS Catalysis) that the R335L / K337G combination mutation of the wild-type terminal deoxynucleotidyl transferase can increase the activity of 3′-ONH2-dNTP. 3′-ONH2 can block the continuous addition of nucleotides, and then remove 3′-ONH2 by NaNO2 to unblock it, which can achieve controlled addition of nucleotides. In the present invention, since the N-terminal Loop region of the wild-type terminal deoxynucleotidyl transferase is truncated, the original R335L / K337G combination mutation is R189L / K191G in the present invention.

[0021] In a third aspect, the present invention provides a gene encoding the terminal deoxynucleotidyl transferase mutant described in the first and second aspects.

[0022] In a fourth aspect, the present invention provides a recombinant vector comprising the above-mentioned encoding gene.

[0023] In a fifth aspect, the present invention provides a genetically engineered bacterium comprising the above-mentioned encoding gene, or comprising the above-mentioned recombinant vector.

[0024] Furthermore, the genetically engineered bacteria is Escherichia coli.

[0025] Furthermore, the genetically engineered bacteria is E. coli BL21 (DE3).

[0026] In a sixth aspect, the present invention provides use of the terminal deoxynucleotidyl transferase mutants in the first and second aspects in enzymatic DNA synthesis.

[0027] In a seventh aspect, the present invention provides a method for enzymatically synthesizing DNA, using deoxyribonucleotides as substrates and synthesizing DNA under the catalytic action of the terminal deoxynucleotidyl transferase mutant described in the second aspect.

[0028] Furthermore, the 3' end of the deoxyribonucleotide is modified with a reversible blocking group; the terminal deoxynucleotidyl transferase mutant is mutated to improve the activity of binding to the deoxyribonucleotide modified with a reversible blocking group at the 3' end.

[0029] The terminal deoxynucleotidyl transferase mutant with high thermal stability provided in the first aspect of the present invention has the property of high temperature resistance after the process of loop truncation and multiple point mutation, and can be adapted to substrate mutation to synthesize DNA using deoxyribonucleotides with different types of reversible blocking groups such as O-amino, O-allyl, O-azido, O-phosphate groups, etc.

[0030] In an eighth aspect, the present invention provides a method for enzymatically synthesizing DNA, using a deoxyribonucleotide modified with an oxyamino group at the 3' end as a substrate,

[0031] Compared with the prior art, the present invention has the following beneficial effects:

[0032] The invention obtains a series of mutants with improved heat resistance by truncating the structure of the wild type terminal deoxynucleotidyl transferase TdT from Zonotrichia albicollis and then performing multi-point mutation. These mutants have better thermal stability and higher unfolding temperature, and can play an important role in DNA enzymatic synthesis. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 Schematic diagram of the protein structure of TdT; the circled part is the Loop structure of the TdT protein.

[0034] Figure 2 The gel electrophoresis diagrams of different mutants; wherein WT-S represents truncated terminal deoxynucleotidyl transferase, N represents the length of the primer, N+1 represents the length of the primer extended by one base, M1 to M7 represent different terminal deoxynucleotidyl transferase mutants, and 37, 56, 58, and 60 represent the incubation temperatures of the proteins.

[0035] Figure 3 The figure is a gel electrophoresis diagram of different mutants; wherein, N represents the length of the primer, N+1 represents the length of the primer extended by one base, M1-1 to M2-9 represent different terminal deoxynucleotidyl transferase mutants, and 37, 62, 64, and 66 represent the incubation temperature of the protein.

[0036] Figure 4 The gel electrophoresis diagrams of different mutants; wherein, N+1 indicates that the length of the primer is extended by one base, WT and LG indicate the mutant WT-S / LG, M2-8 and LG indicate the mutant M2-8 / LG, and 37°C and 58°C indicate the incubation temperature of the protein.

[0037] Figure 5 The extension effects of M2-8 / LG and WT-S / LG are shown in Figure 2, where BIO-52 is the name of the starting primer, and G, T, C, and A represent 3ˊ-ONH2-dGTP, 3ˊ-ONH2-dTTP, 3ˊ-ONH2-dCTP, and 3ˊ-ONH2-dATP, respectively. DETAILED DESCRIPTION

[0038] In order to make those skilled in the art better understand the scheme of the present invention, the technical scheme of the present invention is clearly and completely described below in conjunction with specific embodiments. It should be noted that the following detailed descriptions are all exemplary and are only embodiments of a part of the present invention, rather than all embodiments.

[0039] Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative work should fall within the scope of protection of the present invention.

[0040] Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those of ordinary skill in the art to which this application belongs. The experimental materials used in the examples of the present invention are all conventional experimental materials in the art and can be purchased through commercial channels. Experimental methods without specifying detailed conditions were performed according to conventional experimental methods or according to the operating instructions recommended by the supplier.

[0041] In the following examples, the original terminal deoxynucleotidyl transferase (TdT) used is derived from Zonotrichia albicollis, and its amino acid sequence is shown in SEQ ID NO.1; the truncated terminal deoxynucleotidyl transferase obtained based on the original terminal deoxynucleotidyl transferase has an amino acid sequence shown in SEQ ID NO.2; the amino acid sequence of mutant M1 is shown in SEQ ID NO.3; the amino acid sequence of mutant M2 is shown in SEQ ID NO.4; and the amino acid sequence of mutant M2-8 is shown in SEQ ID NO.5.

[0042] SEQ ID NO.1:

[0043] MDRFKAPAVISQRKRQKGLHSPKLSCSYEIKFSNFVIFIMQRKMGLTRRMFLMELGRRKGFRVESELSDSVTHIVAENNSYLEVLDWLKGQAVGDSSRFELLDISWFTACMEAGRPVDSEVKYRLMEQ SQSLPLNMPALEMPAFIATKVSQYSCQRKTTLNNYNKKFTDAFEVMAENYEFKENEIFCLEFLRAASLLKSLPFSVTRMKDIQGLPCVGDQVRDIIEEIIEEGESSRVNEVLNDERYKAFKQFTSVFG VGVKTSEKWYRMGLRTVEEVKADKTLKLSKMQKAGLLYYEDLVSCVSKAEADAVSLIVKNTVCTFLPDALVTITGGFRRGKNIGHDIDFLITNPGPREDDELLHKVIDLWKKQGLLLYCDIIESTFVK EQLPSRKVDAMDHFQKCFAILKLYQPRVDNSTCNTSEQLEMAEVKDWKAIRVDLVITPFEQYPYALLGWTGSRQFGRDLRRYAAHERKMILDNHGLYDRRKRIFLKAGSEEEIFAHLGLDYVEPWERNA

[0044] SEQ ID NO.2:

[0045] MKVSQYSCQRKTTLNNYNKKFTDAFEVMAENYEFKENEIFCLEFLRAASLLKSLPFSVTRMKDIQGLPCVGDQVRDIIEIIEEEGESSRVNEVLNDERYKAFKQFTSVFGVGVKTSEKWYRMGLRTVEEVKADKTLKLSKMQKAGLLYYEDLVSCVSKAEADAVSLIVKNTVCTFLPDALVTITGGFRRGKNIGHDIDFLITNPGPREDDELLHKVIDLWKKQGLLLYCDIIESTFVKEQLPSRKVDAMDHFQKCFAILKLYQPRVDNSTCNTSEQLEMAEVKDWKAIRVDLVITPFEQYPYALLGWTGSRQFGRDLRRYAAHERKMILDNHGLYDRRKRIFLKAGSEEEIFAHLGLDYVE PWERNA

[0046] SEQ ID NO.3:

[0047] MKVSQYACQRRTTLNNHNKKFTDAFEIMAYEFNENEGRCLAFRRAASVLKSLPFTVTRMKDIQGLPCFGDQVRDIIQEILEHGESSEVKEVLNDERYQAFKLFTSVFGVGVKTAEKWYRMGLRTVEEVKADKTLKLSKMQKAGLLYYEDLVSCVSKAEADAISQIVKETVWTFLPDALVTITGGFRRGKEIGHDVDFLITNPGPREDDELLHKVIDLWKKQGLLLYCDIQESTFVKEQLPSRKVDAMDHFQKCFCILKLYQPRVDNSTCNTSEQLEMAEVKDWKAIRVDLVITPFEQYAFALLGWTGSRQFGRDLRRYARHERKMILDNHGLYDRTQKIFLKATSEEEIFAHLGLDYIEPWERNA

[0048] SEQ ID NO.4:

[0049] MKVSQYACQRRTTLNNHNKRFTDAFEIMAENYEFNENEGRCLAFRRAASVLKSLPFTVTRMKDIQGLPCFGDHVRDIIQEILEHGESSEVKEVLNDERYQAFKLFTSVFGVGVKTAEKWYRMGLRTVEEVKADKTLKLTKMQKAGLQYYEDLVSCVSKAEADAISQIVKETVWTFLPDALVTITGGFRRGKEIGHDVDFLITNPGPREDDELLHKVIDLWKKQGLLLYCDIQESTFDKSKLPSRKVDAMDHFQKCFCILKLYQPRVDNSTCNTSEQLEMAEVKDWKAIRVDLVITPFEQYAFALLGWTGSRQFGRDLRRYARHERKMILDNHGLYDRTQKIFLKATSEEEIFAHLGLEYIEPWERNA

[0050] SEQ ID NO.5:

[0051] MKVSQYACQRRTTLNNHNKRFTDAFEIMAEYYEFNENEGRCLAFRRAASVLKSLPFTVTRMKDIQGLPCFGDHVRRIIQEILEHGESSEVERVLNDERYQAFKLFTSVFGVGVKTAEKWYRMGLRTVEEVKADKTLKLTKMQKAGLQYYEDLVSCVSKAEADAISQIVKETVWAFLPDALVTMTGGFRRGKEIGHDVDFLITNPGPREDDELLHKVIDLWKKQGLLLYCDIIESTFDKSKLPSRKVDAMDHFQKCFCILKLYQPRVDNSTYNTSKQLDMAEVKDWKAVRVDLVVTPYEQYAFALLGWTGSKQFNRDLRRYARHERKMLLDNHGLYDRTQKIFLKATSEEEIFAHLGLEYIPPWERNA。

[0052] Construction of recombinant bacteria of truncated terminal deoxynucleotidyl transferase in Example 1

[0053] The original terminal deoxynucleotidyl transferase (TdT, hereinafter also referred to as WT-L, the amino acid sequence is shown in SEQ ID NO.1) was commissioned to be synthesized by Qingke Biotechnology Co., Ltd. and inserted between the restriction sites BamH I and HindIII of the vector pET28a to obtain the recombinant plasmid pET28a-TdT. The recombinant plasmid was transformed into E. coli BL21 (DE3) competent cells by heat shock method, and the original terminal deoxynucleotidyl transferase recombinant bacteria E. coli BL21 (DE3)-pET28a-TdT was obtained after sequencing verification.

[0054] Alphafold 2 was used to construct the three-dimensional structure of TdT. Based on the model scoring, the appropriate structure was selected and the structure of TdT was observed using pymol. Figure 1 As shown, the first 147 amino acids at the N-terminus were selected as the Loop region to construct a terminal deoxynucleotidyl transferase with N-terminus truncated (hereinafter also referred to as TdT-WT-S). Appropriate primers were designed for whole plasmid PCR.

[0055] Table 1 Primers used to construct truncated terminal deoxynucleotidyl transferase

[0056]

[0057] The primers were synthesized by Beijing Qingke Biotechnology Co., Ltd.

[0058] PCR amplification system:

[0059]

[0060] PCR amplification conditions:

[0061] 1) Pre-denaturation: 98℃ for 3min;

[0062] 2) Denaturation: 98°C for 10 s; annealing: 60°C for 15 s; extension: 72°C for 1 min; 30 cycles in total;

[0063] 3) Post-extension: 72°C for 5 min;

[0064] 4) Store at 4℃.

[0065] Conversion and verification:

[0066] The PCR product was directly transformed into E. coli BL21 (DE3) competent cells using the heat shock method, and the truncated terminal deoxynucleotidyl transferase strain E. coli BL21 (DE3)-TdT-WT-S was obtained after sequencing verification.

[0067] Example 2 Construction of mutants

[0068] The pross online tool based on energy function was used to predict the stability-enhanced mutants of the truncated terminal deoxynucleotidyl transferase TdT-WT-S obtained in Example 1, and the obtained stability-enhanced mutants were M1 to M7, M1-1 to M1-6, and M2-1 to M2-9.

[0069] Mutant M1 was prepared by the truncated terminal deoxynucleotidyl transferase obtained in Example 1 S116A / P301A / L50V / F40R / C173W / A257C / V70F / N192E / L166Q / A322R / Q104L / Y17H / S57T / N91K / I39G / E84H / R89E / K35N / K11R / I82L / G346T / E43A / Y302F / V27I / V164I / S7A / R338T / I232Q / V360I / R340K / N170E / L45R / K339Q / K100Q / I197V / E79Q mutation, mutant M2 was obtained by the truncated terminal deoxynucleotidyl transferase obtained in Example 1, S116A / P301A / L50V / F40R / C173W / A257C / V70F / N192E / L166Q / A322R / Q104L / Y17H / S57T / N91K / I39G / E84H / R89E / K35N / K11R / I82L / G346T / E43A / Y302F / V27I / V164I / S7A / R338T / I232Q / V360I / R340K / N170E / L45R / K339Q / K Mutant M3 was obtained by subjecting the truncated terminal deoxynucleotidyl transferase obtained in Example 1 to S116A / P301A / L50V / F40R / C173W / A257C mutations, and mutant M4 was obtained by subjecting the truncated terminal deoxynucleotidyl transferase obtained in Example 1 to S116A / P301A / L50V / F40R / C173W / A257C / V70I / N192E / L166Q / A322R mutations. Mutant M5 was obtained by subjecting the truncated terminal deoxynucleotidyl transferase obtained in Example 1 to S116A / P301A / L50V / F40R / C173W / A257C / V70I / N192E / L166Q / A322R / Q104L mutations, and mutant M6 was obtained by subjecting the truncated terminal deoxynucleotidyl transferase obtained in Example 1 to S116A / P301A / L50V / F40R / C173W / A257C / V70F / N192E / L166Q / A322R / Q104L / Y17H / S57T / N91K / I39G / E84H mutations.Mutant M7 was obtained by subjecting the truncated terminal deoxynucleotidyl transferase obtained in Example 1 to S116A / P301A / L50V / F40R / C173W / A257C / V70F / N192E / L166Q / A322R / Q104L / Y17H / S57T / N91E / I39G / E84H / R89E / K35N / K11R / I82L / G346T / E43A / Y302F / V27I / V164I / S7A / R338T / I232Q mutations.

[0070] Mutant M1-1 was obtained by subjecting mutant M1 to G314N mutation, mutant M1-2 was obtained by subjecting mutant M1 to G314N / Q232I mutation, mutant M1-3 was obtained by subjecting mutant M1 to G314N / Q232I / I328L / E275K mutation, mutant M1-4 was obtained by subjecting mutant M1 to G314N / Q232I / I328L / E275K / I183M / D76R mutation, and mutant M1-5 was obtained by subjecting mutant M1 to G314N / Q23 2I / I328L / E275K / I183M / D76R / T270N / R311K / M28L / E92R / A101T mutations were performed on mutant M1. Mutant M1-6 was obtained by performing G314N / Q232I / I328L / E275K / I183M / D76R / T270N / R311K / M28L / E92R / A101T / V237E / T174A / Q240K / K20R / F297W / D358E / C271Y mutations on mutant M1.

[0071] Mutant M2-1 was obtained by subjecting mutant M2 to G314N / E361P mutation, mutant M2-2 was obtained by subjecting mutant M2 to G314N / E361P / Q232I mutation, mutant M2-3 was obtained by subjecting mutant M2 to G314N / E361P / Q232I / I183M mutation, and mutant M2-4 was obtained by subjecting mutant M2 to G314N / E361P / Q232I / I183M / I328L mutation. Mutant M2-5 was obtained by subjecting mutant M2 to G314N / E361P / Q232I / I183M / I328L / N31Y mutations, mutant M2-6 was obtained by subjecting mutant M2 to G314N / E361P / Q232I / I183M / I328L / N31Y / E275K / D76R mutations, and mutant M2-7 was obtained by subjecting mutant M2 to G314N / E361P / Q232I / I183M / I328L / N31Y / E275K / D76R mutations. Mutant M2-8 was obtained by mutation of mutant M2 with G314N / E361P / Q232I / I183M / I328L / N31Y / E275K / D76R / R311K / I288V / C271Y / T174A / K91E / F297Y / E92R / E278D / I294V, and mutant M2-9 was obtained by mutation of mutant M2 with G314N / E361P / Q232I / I183M / I328L / N31Y / E275K / D76R / R311K / I288V / C271Y / T174A / K91E / F297Y / E92R / E278D / I294V. Mutant M2 was obtained by undergoing G314N / E361P / Q232I / I183M / I328L / N31Y / E275K / D76R / R311K / I288V / C271Y / T174A / K91E / F297W / E92R / E278D / V216I / V153S / T270N / S239T / S165A / Q276E / M28L / M249L / K344H / F56Y / D291H mutations.

[0072] R189L / K191G mutations were performed on WT-S and M2-8 to obtain WT-S / LG and M2-8 / LG.

[0073] The mutant gene was synthesized by Qingke Biotechnology Co., Ltd. and inserted into the restriction sites BamH I and Hind III of the vector pET28a to obtain the recombinant plasmid.

[0074] Example 3 Expression and purification of different terminal deoxynucleotidyl transferase mutants

[0075] The heat shock method was used to transform plasmids carrying different terminal deoxynucleotidyl transferase mutant genes (M1-7, M1-1-M1-6, M2-1-M2-9, WT-S / LG, M2-8 / LG) or truncated terminal deoxynucleotidyl transferase WT-S into E. coli BL21 (DE3) competent cells. After sequencing verification, recombinant bacteria containing different terminal deoxynucleotidyl transferase mutant genes were obtained.

[0076] The obtained recombinant strain was spread on LB solid medium containing 50 μg / mL kanamycin (Kana), and cultured in a 37°C constant temperature incubator for 12 h; a single colony was picked and inoculated into 5 mL LB liquid medium containing 50 μg / mL Kana, and cultured at 37°C, 220 rpm for 8-12 h; the inoculum was transferred to 50 mL of fresh LB liquid medium containing 50 μg / mL Kana at a 2% inoculum volume, and cultured at 37°C, 220 rpm until OD 600 When the pH value reached about 0.8, IPTG was added at a final concentration of 1 mM and the culture was induced at 18°C ​​and 220 rpm for 16 h.

[0077] After the culture is completed, the bacterial solution is centrifuged at 4000rpm and 4℃ for 15min, the supernatant is discarded, and the collected bacteria are then resuspended in 50mM phosphate buffer with pH 7.5, and ultrasonically disrupted at 400W in an ice water bath, each ultrasonication for 3S, with an interval of 7S. After the disruption is completed, the cell disruption solution is centrifuged at 12000rpm and 4℃ for 30min to remove cell debris, and the obtained supernatant is the crude enzyme solution, which is filtered through a 0.22μm filter membrane for purification, and impurities are washed with a washing buffer (50mM PBS buffer, 50mM imidazole, 100mM NaCl, pH7.5), and the target protein is eluted with an elution buffer (50mM PBS buffer, 250mM imidazole, 100mM NaCl, pH 7.5). The separated target protein is placed in an ultrafiltration centrifuge tube for sufficient desalting and concentration to obtain pure terminal deoxynucleotidyl transferase mutant proteins.

[0078] Example 4 Stability Characterization of Different Terminal Deoxynucleotidyl Transferase Mutants

[0079] The stability of different terminal deoxynucleotidyl transferase mutants was tested as follows:

[0080] Different terminal deoxynucleotidyl transferase mutant proteins purified in Example 3 were dissolved in PBS buffer to prepare enzyme solutions with a concentration of 0.2 mg / mL. The enzyme solutions with a concentration of 0.2 mg / mL were incubated at 56 / 58 / 60 / 62 / 64 / 66°C for 5 min and then placed on ice for use. The reaction system included 1 μM primer N, 33 μM ddGTP, 0.25 mM CoCl2, 100 mM NaCl and 50 mM phosphate buffer (pH 7.5). The enzyme solution of the terminal deoxynucleotidyl transferase mutant after incubation of 0.02 mg / mL was reacted at 37°C for 3 min, and the reaction was analyzed by 20% urea-polyacrylamide gel electrophoresis. The results are shown in FIG. Figure 2-3 shown.

[0081] The WT-S / LG and M2-8 / LG proteins purified in Example 3 were dissolved in PBS buffer to prepare an enzyme solution with a concentration of 0.5 mg / mL. The enzyme solution with a concentration of 0.5 mg / mL was incubated at 37 / 58 / 61°C for 5 min and then placed on ice for use. The reaction system included 1 μM primer N, 33 μM 3′-ONH2-dGTP, 0.25 mM CoCl2, 100 mM NaCl and 50 mM phosphate buffer (pH 7.5). The 0.05 mg / mL incubated enzyme solution was reacted at 37°C for 10 min, and the reaction was analyzed by 20% urea-polyacrylamide gel electrophoresis. The results are shown in FIG. Figure 4 shown.

[0082] According to Figure 2-3 The gel electrophoresis image shown was used for grayscale extraction using SHST analysis to measure the grayscale of the extended product and the grayscale of the unextended band. The yield was calculated using the ratio of the grayscale of the extended product to the sum of the grayscales of the extended and unextended bands in the lane. The results are shown in Tables 2, 3, and 4.

[0083] Table 2 Product yields of terminal deoxynucleotidyl transferase mutants M1-7 at different temperatures

[0084]

[0085] Table 3 Product yields of terminal deoxynucleotidyl transferase mutants M1-1 to M1-6 at different temperatures

[0086]

[0087]

[0088] Table 4 Product yields of terminal deoxynucleotidyl transferase mutants M2-2 to M2-8 at different temperatures

[0089]

[0090] Example 5 Unfolding Temperature T of Different Terminal Deoxynucleotidyl Transferase Mutants m Determination of

[0091] The unfolding temperature T of the mutants was determined using a protein thermal stability analyzer (NanoTemper, USA). m A protein sample with a concentration of 0.5 mg / mL was loaded into a quartz capillary, the power was set to 10%, the scanning rate was 60 °C / h, and the scanning range was 20-90 °C.

[0092] Unfolding temperature T of different terminal deoxynucleotidyl transferase mutants m As shown in Table 5.

[0093] Table 5 Terminal deoxynucleotidyl transferase unfolding temperature T m

[0094]

[0095] Depend on Figure 2 , Figure 3 As can be seen from Table 5, M1, M2, M1-4, M1-5, M1-6, M2-2, M2-3, M2-4, M2-5, M2-6, and M2-8 have higher unfolding temperatures than the truncated terminal deoxynucleotidyl transferase, indicating that they have higher thermal stability.

[0096] Example 6 Application of thermostable terminal deoxynucleotidyl transferase in DNA synthesis

[0097] Studies have shown (Enzymatic DNA Synthesis by Engineering Terminal Deoxynucleotidyl Transferase | ACS Catalysis) that the R335L / K337G combined mutation of WT-L can increase the activity of 3′-ONH2-dNTP. 3′-ONH2 can block the continuous addition of nucleotides, and then remove 3′-ONH2 by NaNO2 for unblocking, which can achieve controlled addition of nucleotides. In Example 1, the N-terminal Loop region of WT-L was truncated, so the 335th and 337th positions of WT-L are the 189th and 191st positions of different mutants obtained later in the example.

[0098] In this example, the M2-8 / LG combined mutant obtained in Example 1 was subjected to DNA extension at high temperature. The specific steps are as follows:

[0099] (1) Construction of WT-S / LG and M2-8 / LG

[0100] Table 6 Construction of WT-S / LG and M2-8 / LG

[0101]

[0102] The primers were synthesized by Beijing Qingke Biotechnology Co., Ltd.

[0103] PCR amplification system:

[0104]

[0105] PCR amplification conditions:

[0106] 1) Pre-denaturation: 98℃ for 3min;

[0107] 2) Denaturation: 98°C for 10 s; annealing: 60°C for 15 s; extension: 72°C for 1 min; 30 cycles in total;

[0108] 3) Post-extension: 72°C for 5 min;

[0109] 4) Store at 4℃.

[0110] Conversion and verification:

[0111] The PCR products were directly transformed into E. coli BL21 (DE3) competent cells using the heat shock method, and the truncated terminal deoxynucleotidyl transferase strains E. coli BL21 (DE3)-TdT-M2-6 / LG and E. coli BL21 (DE3)-TdT-WT-S / LG were obtained after sequencing verification.

[0112] (2) Purify M2-8 / LG protein and WT-S / LG protein in the manner of Example 3, dissolve in PBS buffer to prepare an enzyme solution with a concentration of 0.7 mg / mL, incubate BIO-52 primers and magnetic beads at 37°C for 30 min, the reaction system includes primers, 150 μM 3′-ONH2-dNTP, 0.25 mM CoCl2, 100 mM NaCl and 50 mM phosphate buffer (pH 7.5), and the 0.07 mg / mL incubated enzyme solution is reacted at 55°C for 30 min; after the reaction, incubate with 700 mM NaNO2 for 10 min. Repeat the above process for stepwise extension of nucleotides, and analyze the reaction status by 20% urea-polyacrylamide gel electrophoresis.

[0113] Results Figure 5 A and Figure 5 B, where Figure 5 A is the M2-8 / LG extension effect diagram. Figure 5 B is the WT-S / LG extension effect diagram.

Claims

1. A terminal deoxynucleotidyl transferase mutant with high thermal stability, characterized in that: The following mutation form is one of the following forms: (1) The amino acid sequence of SEQ ID NO.2 was mutated to S116A / P301A / L50V / F40R / C173W / A257C / V70F / N192E / L166Q / A322R / Q104L / Y17H / S57T / N91K / I39G / E84H / R89E / K35N / K11R / I82L / G346T / E43A / Y302F / V27I / V164I / S7A / R338T / I232Q / V360I / R340K / N170E / L45R / K339Q / K100Q / I197V / E79Q, and the amino acid sequence is shown in SEQ ID NO.3; (2) The amino acid sequence of SEQ ID NO. 2 was modified into S116A / P301A / L50V / F40R / C173W / A257C / V70F / N192E / L166Q / A322R / Q104L / Y17H / S57T / N91K / I39G / E84H / R89E / K35N / K11R / I82L / G346T / E43A / Y30 2F / V27I / V164I / S7A / R338T / I232Q / V360I / R340K / N170E / L45R / K339Q / K100Q / I197V / E79Q / V237D / S139T / Q73H / Q240K / L147Q / K20R / E239S / D358E was obtained by mutation, and the amino acid sequence is shown in SEQ ID NO.4; (3) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 3 to G314N / Q232I / I328L / E275K / I183M / D76R mutations; (4) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 3 to G314N / Q232I / I328L / E275K / I183M / D76R / T270N / R311K / M28L / E92R / A101T mutations; (5) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 3 to G314N / Q232I / I328L / E275K / I183M / D76R / T270N / R311K / M28L / E92R / A101T / V237E / T174A / Q240K / K20R / F297W / D358E / C271Y mutations; (6) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 4 to G314N / E361P / Q232I mutations; (7) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 4 to G314N / E361P / Q232I / I183M mutations; (8) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 4 to G314N / E361P / Q232I / I183M / I328L mutations; (9) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 4 to G314N / E361P / Q232I / I183M / I328L / N31Y mutations; (10) obtained by subjecting the amino acid sequence shown in SEQ ID NO. 4 to G314N / E361P / Q232I / I183M / I328L / N31Y / E275K / D76R mutations; (11) The amino acid sequence shown in SEQ ID NO.4 was mutated to G314N / E361P / Q232I / I183M / I328L / N31Y / E275K / D76R / R311K / I288V / C271Y / T174A / K91E / F297Y / E92R / E278D / I294V, and the amino acid sequence is shown in SEQ ID NO.

5.

2. A terminal deoxynucleotidyl transferase mutant, characterized in that The mutant according to claim 1 is obtained by subjecting the mutant to R189L / K191G mutation.

3. The terminal deoxynucleotidyl transferase mutant according to claim 2, characterized in that It was obtained by performing R189L / K191G on the amino acid sequence shown in SEQ ID NO.

5.

4. A gene encoding the terminal deoxynucleotidyl transferase mutant according to any one of claims 1 to 3.

5. A recombinant vector, characterized in that: Comprising the gene as claimed in claim 4.

6. A genetically engineered bacterium, characterized in that: Comprising the gene as claimed in claim 4, or comprising the recombinant vector as claimed in claim 5.

7. Use of the terminal deoxynucleotidyl transferase mutant according to any one of claims 1 to 3 in enzymatic DNA synthesis.

8. A method for enzymatically synthesizing DNA, characterized in that: Using deoxyribonucleotide as substrate, DNA is synthesized under the catalysis of the terminal deoxynucleotidyl transferase mutant as claimed in claim 1.

9. The method for enzymatically synthesizing DNA according to claim 8, characterized in that: The 3' end of the deoxyribonucleotide is modified with a reversible blocking group; the terminal deoxynucleotidyl transferase mutant is mutated to improve the activity of binding to the deoxyribonucleotide modified with the reversible blocking group at the 3' end.

10. A method for enzymatically synthesizing DNA, characterized in that: DNA is synthesized under the catalysis of the terminal deoxynucleotidyl transferase mutant described in claim 2 using deoxyribonucleotides modified with 3'-end oxygen amino groups as substrates.

Citation Information

Patent Citations

  • Terminal deoxynucleotidyl transferase variants and uses thereof

    CN113302289A

  • Terminal deoxynucleotidyl transferase mutant as well as composition and preparation method thereof

    CN116716273A

  • Thermostable terminal deoxynucleotidyl transferase

    US20210355460A1

  • Modified terminal deoxynucleotidyl transferase (TDT) enzymes

    US20220119781A1

  • Engineered Terminal Deoxynucleotidyl Transferase Variants

    US20240182876A1

Cited By

  • Controllable synthesized single-stranded DNA terminal deoxynucleotidyl transferase mutant and application thereof

    CN119570761A

  • Terminal deoxyribonucleotide transferase mutant, preparation method and kit

    CN120624399A

  • Terminal deoxyribonucleotidyl transferase mutants, their preparation methods, and reagent kits

    CN120624399B